Stocks · News reference
Bayer (OTC:BAYRY) affirms FY2026 currency-adjusted Adj EPS guidance from $1.20-$1.35 to $1.20-$1.35 vs $1.25 analyst estimate. Affirms FY2026 currency-adjusted sales outlook from $52.109 billion-$54.451 billion to
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bayer (OTC:BAYRY) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.23 by 21.74 percent. This is a 20 percent decrease over earnings of $0.35 per share from the same period
Read original at benzingaThe global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.
Read original at globenewswire-incOrion reported strong H1 2026 results with revenue of €939.3 million (+21.8% YoY) and operating profit of €291.3 million (+59.6% YoY). The company raised its 2026 guidance, expecting revenue of €2,000-2,100 million and operating profit of €650-750 million. Key drivers include growth in Nubeqa royalties, FDA approval for Animal Health product Tessie®, and significant progress in ODM-212 cancer drug development with orphan drug designations.
Read original at globenewswire-inc